α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy

α-Synuclein Aggregation in Treatment of Parkinson's Disease

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys - eBioMedicine

Pathological roles of α-synuclein in neurological disorders - The Lancet Neurology

Stress-induced p53 drives BAG5 cochaperone expression to control α-synuclein aggregation in Parkinson's disease - Figure f6

Targeting Alpha Synuclein Aggregation with CBP/p300 Inhibitors: A Novel Approach in Parkinson's Disease Therapeutics

Alpha Synuclein Assay

Frontiers Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease

Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates

Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage

Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease

HTRF Phospho-A-Synuclein Ser129 aggregation